120 related articles for article (PubMed ID: 12387843)
1. Challenges of PK/PD measurements in modern drug development.
Workman P
Eur J Cancer; 2002 Nov; 38(16):2189-93. PubMed ID: 12387843
[No Abstract] [Full Text] [Related]
2. [Heat shock protein 90: novel target for cancer therapy].
Chen Y; Ding J
Ai Zheng; 2004 Aug; 23(8):968-74. PubMed ID: 15301726
[TBL] [Abstract][Full Text] [Related]
3. The role of functional and molecular imaging in cancer drug discovery and development.
Seddon BM; Workman P
Br J Radiol; 2003; 76 Spec No 2():S128-38. PubMed ID: 15572335
[TBL] [Abstract][Full Text] [Related]
4. Heat shock protein inhibitor shows antitumor activity.
Dunn FB
J Natl Cancer Inst; 2002 Aug; 94(16):1194-5. PubMed ID: 12189221
[No Abstract] [Full Text] [Related]
5. Cancer: the rules of attraction.
Neckers L; Lee YS
Nature; 2003 Sep; 425(6956):357-9. PubMed ID: 14508471
[No Abstract] [Full Text] [Related]
6. Protein chaperones as anticancer therapy targets.
Sausville E
Clin Adv Hematol Oncol; 2004 Feb; 2(2):92-3. PubMed ID: 16163168
[No Abstract] [Full Text] [Related]
7. Auditing the pharmacological accounts for Hsp90 molecular chaperone inhibitors: unfolding the relationship between pharmacokinetics and pharmacodynamics.
Workman P
Mol Cancer Ther; 2003 Feb; 2(2):131-8. PubMed ID: 12589030
[No Abstract] [Full Text] [Related]
8. Altered Hsp90 function in cancer: a unique therapeutic opportunity.
Bagatell R; Whitesell L
Mol Cancer Ther; 2004 Aug; 3(8):1021-30. PubMed ID: 15299085
[TBL] [Abstract][Full Text] [Related]
9. Overview: translating Hsp90 biology into Hsp90 drugs.
Workman P
Curr Cancer Drug Targets; 2003 Oct; 3(5):297-300. PubMed ID: 14529382
[TBL] [Abstract][Full Text] [Related]
10. Regulation of glucocorticoid receptor steroid binding and trafficking by the hsp90/hsp70-based chaperone machinery: implications for clinical intervention.
Murphy PJ
Leukemia; 2005 May; 19(5):710-2. PubMed ID: 15759036
[No Abstract] [Full Text] [Related]
11. Heat shock protein and proteasome targeting agents.
Takimoto CH; Diggikar S
Hematol Oncol Clin North Am; 2002 Oct; 16(5):1269-85. PubMed ID: 12512392
[TBL] [Abstract][Full Text] [Related]
12. Heat shock protein 90 indirectly regulates ERK activity by affecting Raf protein metabolism.
Dou F; Yuan LD; Zhu JJ
Acta Biochim Biophys Sin (Shanghai); 2005 Jul; 37(7):501-5. PubMed ID: 15999212
[TBL] [Abstract][Full Text] [Related]
13. FLT3 expressing leukemias are selectively sensitive to inhibitors of the molecular chaperone heat shock protein 90 through destabilization of signal transduction-associated kinases.
Yao Q; Nishiuchi R; Li Q; Kumar AR; Hudson WA; Kersey JH
Clin Cancer Res; 2003 Oct; 9(12):4483-93. PubMed ID: 14555522
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models.
Banerji U; Walton M; Raynaud F; Grimshaw R; Kelland L; Valenti M; Judson I; Workman P
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):7023-32. PubMed ID: 16203796
[TBL] [Abstract][Full Text] [Related]
15. Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin.
da Rocha Dias S; Friedlos F; Light Y; Springer C; Workman P; Marais R
Cancer Res; 2005 Dec; 65(23):10686-91. PubMed ID: 16322212
[TBL] [Abstract][Full Text] [Related]
16. Synthetic lethality: killing cancer with cancer.
Garber K
J Natl Cancer Inst; 2002 Nov; 94(22):1666-8. PubMed ID: 12441317
[No Abstract] [Full Text] [Related]
17. Targeting toxic proteins for turnover.
La Spada AR; Weydt P
Nat Med; 2005 Oct; 11(10):1052-3. PubMed ID: 16211038
[No Abstract] [Full Text] [Related]
18. Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors.
Smith-Jones PM; Solit DB; Akhurst T; Afroze F; Rosen N; Larson SM
Nat Biotechnol; 2004 Jun; 22(6):701-6. PubMed ID: 15133471
[TBL] [Abstract][Full Text] [Related]
19. Structure and in vivo function of Hsp90.
Pearl LH; Prodromou C
Curr Opin Struct Biol; 2000 Feb; 10(1):46-51. PubMed ID: 10679459
[TBL] [Abstract][Full Text] [Related]
20. Clinical trials referral resource. Current clinical trials of 17-AG and 17-DMAG.
Ivy PS; Schoenfeldt M
Oncology (Williston Park); 2004 May; 18(5):610, 615, 619-20. PubMed ID: 15209189
[No Abstract] [Full Text] [Related]
[Next] [New Search]
